SUMMARY

• The company cannot recommend any practices, procedures or usage that deviate from the approved labeling.
• Data from a retrospective chart review of the use of TREMFYA in combination with dupilumab are summarized.

CLINICAL DATA

Retrospective Chart Review

Barry et al (2021)¹ reported on the use of dupilumab in combination with biologics for plaque psoriasis (PsO), including TREMFYA.

Study Design/Methods

• A retrospective chart review from the Tufts Medical Center Department of Dermatology assessed the use of dupilumab in combination with a biologic between January 1, 2016, and May 1, 2019, in patients with atopic dermatitis (AD) and plaque PsO or bullous pemphigoid (BP) and plaque PsO.
• A minimum of 1 follow-up appointment was required ≥6 weeks after the initiation of dual biologic therapy for study inclusion.
• Clinical response was classified qualitatively based on changes in body surface area (BSA) involvement and Investigator’s Global Assessment (IGA) and Physician’s Global Assessment (PGA) scores.

Results

• Seven patients (Caucasian, 71%; Asian, 29%; female, 43%; mean age, 61 years; age range, 31-78 years) presented with plaque PsO and AD (n=6) or plaque PsO and BP (n=1).
• All 7 patients failed prior topical treatments, and 3 previously failed other biologic monotherapy.
• All patients completed combination TREMFYA and dupilumab (300 mg biweekly [n=5] or weekly [n=2]) treatment for 2-13 months (mean, 6.4 months; median, 6 months).
• Clinical response to combination TREMFYA and dupilumab treatment is depicted in Table: Demographic and Response Summary. Positive clinical response was defined as a reduction in BSA involvement and IGA score for dupilumab, and a reduction in BSA involvement and PGA score for TREMFYA.

Literature Search

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, and DERWENT^® (and/or other resources, including internal/external databases) was conducted on 21 May 2024.